Ascorbic Acid + Chemotherapy for Lymphoma
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that patients on ibrutinib or corticosteroids may continue therapy until the new regimen starts, at the investigator's discretion. It's best to discuss your specific medications with the trial team.
What evidence supports the effectiveness of the drug combination including Ascorbic Acid and Rituximab for treating lymphoma?
Research shows that adding rituximab to chemotherapy regimens for lymphoma, such as R-CHOP, improves treatment outcomes and survival rates. Rituximab has been effective in enhancing the response to chemotherapy in various types of lymphoma, suggesting potential benefits when combined with other drugs like Ascorbic Acid.12345
Is the combination of ascorbic acid and chemotherapy drugs like carboplatin and cisplatin safe for humans?
Research shows that carboplatin and cisplatin, when used together, can have manageable side effects like low blood cell counts, nausea, and vomiting, but they are generally considered safe with careful monitoring. Carboplatin is noted for having fewer kidney-related side effects compared to cisplatin, making it a safer option in some cases.678910
What makes the Ascorbic Acid + Chemotherapy treatment for lymphoma unique?
This treatment combines ascorbic acid (vitamin C) with a mix of chemotherapy drugs, including rituximab, which has shown improved response rates and survival in lymphoma patients. The unique aspect is the addition of ascorbic acid, which may enhance the effectiveness of chemotherapy, although its precise role in lymphoma treatment is still being studied.12111213
What is the purpose of this trial?
This trial tests if adding high doses of vitamin C to standard chemotherapy can better treat certain cancers that have returned or are resistant to treatment. The goal is to see if vitamin C makes the chemotherapy more effective at killing cancer cells. The study focuses on patients with specific types of lymphoma, CCUS, and CMML. High-dose intravenous vitamin C (IVC) has been explored for its potential to enhance the effectiveness of cancer chemotherapy, with some clinical evidence suggesting benefits, though rigorous data are lacking.
Research Team
Thomas E. Witzig, M.D.
Principal Investigator
Mayo Clinic
Eligibility Criteria
Adults with recurrent or refractory lymphoma, including various subtypes like Diffuse Large B-Cell Lymphoma, who haven't responded to therapy within 6 months or have relapsed after a response lasting more than 6 months. Participants must be in good physical condition (ECOG PS 0-2), able to return for follow-up, and have measurable disease. They should not be pregnant/nursing and must agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ascorbic acid and combination chemotherapy. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion. Follow-up occurs every 3 months, then every 6 months after progressive disease for up to 2 years.
Extension
Participants with stable disease after 12 cycles may continue decitabine with or without ascorbic acid as long as clinically appropriate.
Treatment Details
Interventions
- Ascorbic Acid
- Carboplatin
- Cisplatin
- Cytarabine
- Dexamethasone
- Etoposide
- Gemcitabine Hydrochloride
- Ifosfamide
- Rituximab
Carboplatin is already approved in United States, European Union, Canada for the following indications:
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Head and neck cancer
- Brain cancer
- Ovarian cancer
- Small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborator